Holen Sie sich die Stockscreener-App
179.25
1.55%
-2.82
Schlusskurs vom Vortag:
$182.07
Offen:
$182.55
24-Stunden-Volumen:
982.67K
Relative Volume:
1.40
Marktkapitalisierung:
$9.39B
Einnahmen:
$708.24M
Nettoeinkommen (Verlust:
$-188.30M
KGV:
-47.94
EPS:
-3.7392
Netto-Cashflow:
$-70.99M
1W Leistung:
-8.12%
1M Leistung:
-14.61%
6M Leistung:
+6.38%
1J Leistung:
+49.45%
1-Tages-Spanne:
$175.46
$182.55
1-Wochen-Bereich:
$175.46
$198.96
52-Wochen-Spanne:
$117.30
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
179.25 | 10.22B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM) - theglobeandmail.com
Responsive Playbooks and the AXSM Inflection - Stock Traders Daily
Deutsche Bank Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $267 - Moomoo
EBITDA per share of Axsome Therapeutics, Inc. – HAN:19X - TradingView
Axsome Therapeutics Is Maintained at Buy by Deutsche Bank - Moomoo
Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade - MarketBeat
Axsome Therapeutics slides as investors weigh launch execution and policy risks - Quiver Quantitative
Axsome Therapeutics, Inc. Revenue Breakdown – HAN:19X - TradingView
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $267.00 by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - marketscreener.com
Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley - moomoo.com
AXSM Maintains Rating by Morgan Stanley -- Price Target Lowered to $247 - GuruFocus
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251 - Moomoo
H.C. Wainwright reiterates Axsome stock Buy rating at $290 target - Investing.com
H.C. Wainwright reiterates Axsome stock Buy rating at $290 target By Investing.com - Investing.com Canada
AXSOME THERAPEUTICS, INC. : TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $285 VS $200 - webull.com
$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga
AXSM Stock Price and Chart — NASDAQ:AXSM - TradingView
10 Health Care Stocks Whale Activity In Today’s Session - benzinga.com
Truist Securities maintains Buy rating on Axsome Therapeutics, $285 price target - TradingView
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - marketscreener.com
Truist initiates Axsome stock coverage with buy rating on growth By Investing.com - Investing.com Nigeria
Truist initiates Axsome stock coverage with buy rating on growth - Investing.com
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day - The Manila Times
Axsome Therapeutics Announces Results of the Shared Goals - GlobeNewswire
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Promising 37% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction - MarketBeat
Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues - Yahoo Finance
Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story? - Yahoo Finance
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference - MarketBeat
Bank of America Corp DE Acquires Shares of 452,491 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics (AXSM) Reported New Clinical Data In Depression And Alzheimer’s Agitation - Yahoo Finance
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy? - Yahoo Finance
Axsome Therapeutics (NASDAQ:AXSM) Receives "Overweight" Rating from Piper Sandler - MarketBeat
Axsome Therapeutics Price Target Maintained With a $258.00/Share by Piper Sandler - Moomoo
Piper Sandler reiterates Overweight rating on Axsome Therapeutics, $258 price target - TradingView
Axsome's Auvelity Launch Shows Early Strength in Alzheimer's Agitation, RBC Says - Yahoo Finance
Is Axsome Therapeutics a Buy on the Dip? - Yahoo Finance
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 - The Manila Times
Axsome Therapeutics Presents Ten Posters Exemplifying its - GlobeNewswire
Baird Financial Group Inc. Acquires New Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Ten posters cover depression, Alzheimer’s agitation and narcolepsy - Stock Titan
Axsome Therapeutics at H.C. Wainwright conference: growth broadens By Investing.com - Investing.com South Africa
Axsome Therapeutics at H.C. Wainwright conference: growth broadens - Investing.com
Engineers Gate Manager LP Has $2.74 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics at Morgan Stanley conference: growth, pipeline and cash - Investing.com
Axsome Therapeutics, Inc. (AXSM) Investor Outlook: A Biotech Stock with 29% Upside and Robust Growth Potential - DirectorsTalk Interviews
About Axsome Therapeutics, Inc. rStock - Coinbase
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Sep 03 '26 |
Sale |
208.65 |
10,000 |
2,086,500 |
0 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):